Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-04-30

FDA Approved: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE — Supplemental Application (Zydus Lifesciences Limited)

View source ↗

Summary

FDA approved a supplemental application from Zydus Lifesciences Limited for a generic fixed-dose combination of candesartan cilexetil and hydrochlorothiazide fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Candesartan Cilexetil and Hydrochlorothiazide (Candesartan cilexetil and hydrochlorothiazide)

Snippet

SUPPL AP for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE (CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE)